Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Revenues

TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2020. Profound is providing this information due to the significant lag time between planned investment community meetings to be held in connection with, among other investor events, the 39th Annual J.P. Morgan Healthcare Conference, and its expected reporting of final 2020 results in March 2021.